tirzepatide nad for Rapid and Sustainable Fat Loss Results Molecular structure of tirzepatide and

From your initial consultation to medication delivery, everything is handled seamlessly onlineallowing you to achieve your health goals without the hassle

Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)

Who Should Choose Which Medication

Rated 5 out of 5 Anonymous (verified owner) Still doing great on my meds